BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly
docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor …

The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the
combination of weekly docetaxel and gemcitabine in patients with advanced non–small-cell …

Administering docetaxel weekly at a relatively low dose minimizes myelosuppression and
reduces nonhematologic toxicities. In a community-based phase II trial conducted in 39 …

Purpose This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin
over docetaxel monotherapy in elderly patients with advanced non–small-cell lung cancer …

Background: We conducted a multicenter randomized phase II trial to evaluate two
schedules of single-agent docetaxel in the first-line treatment of elderly and performance …

BACKGROUND Weekly administration of docetaxel was found to reduce myelosuppression
and other nonhematologic toxicities when compared with administration every 3 weeks. In …

Introduction We report outcomes for a phase II study of the combination of weekly docetaxel
and cisplatin in elderly patients with advanced non-small cell lung cancer. Methods Patients …

CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly
docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung …

7057 Background: Docetaxel has been used in elderly and PS 2 pts with advanced NSCLC
with acceptable toxicity. However, myelosuppression can be severe on the every 3-week …

Purpose Docetaxel has shown activity in elderly patients with advanced non–small-cell lung
cancer (NSCLC). This randomized phase III trial evaluated the efficacy and safety of …